Below are the most recent publications written about "Inflammation" by people in Profiles.
-
Shepard DM, Hahn S, Chitre M, Neff H, Ward DV, Jadhav N, Richmond JM, Ramirez-Ortiz ZG. SCARF1 deficiency exacerbates gut inflammation and autoimmune pathology. Sci Rep. 2026 Feb 11; 16(1).
-
Wang Q, Li J, Yang M, Guo C, Zhang M, Huang C, Wang X, Zhang D, Zeng L, Ke H, Wen Y, Li S, Lee W, Zhao L, Lan X, Xiang Y. Peptide OH-CATH30 Mitigates Cachexia-Induced Muscle Atrophy via Modulation of TLR4-Associated Inflammation. J Cachexia Sarcopenia Muscle. 2026 Feb; 17(1):e70195.
-
Merbecks AJ, Mennicken C, de Graaf DM, Shkarina K, Wagner T, Latz E. Western lifestyle linked to maladaptive trained immunity. Elife. 2026 Jan 21; 15.
-
Koerber RM, Krollmann C, Cieslak K, Tregel E, Saenz ML, Br?mmendorf TH, Koschmieder S, Griesshammer M, G?tgemann I, Baldauf CK, Fischer T, Brossart P, Kolbe CC, Latz E, Wolf D, Teichmann LL. NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms. Nat Commun. 2025 Nov 26; 16(1):10591.
-
Merrill LC, Thomas E, Wright JR, Lamendella R, Bhandari S, Bello D, Kelleher SL, Tucker KL, Mangano KM. Food grade titanium dioxide is related to gut dysbiosis, but not markers of intestinal inflammation nor permeability in healthy, young adults. NanoImpact. 2025 Oct; 40:100594.
-
Baran A, Nowowiejska J, Parzych J, Hermanowicz JM, Sieklucka B, Pawlak D, Flisiak I. Plasma Galectin-4 and Charcot-Leyden Crystal Protein/Galectin-10 as Emerging Biomarkers of Metabolically Induced Inflammation in Patients with Psoriasis. Int J Mol Sci. 2025 Oct 23; 26(21).
-
Fink A, Reinke C, Aretz B, Heneka MT, Doblhammer G. Can vigorous physical activity mitigate the effect of systemic inflammation on cognitive performance? Results from a large older community dwelling population in The Netherlands. J Alzheimers Dis. 2025 Dec; 108(3):1369-1377.
-
Yang YS, Kim MJ, Chaugule S, Mayer E, DeSouza N, Ma H, Xie J, Lee KY, Li S, Gravallese E, Gao G, Shim JH. Nature-inspired IL-1 targeted therapy to treat chronic inflammatory diseases. Mol Ther. 2025 Dec 03; 33(12):6379-6397.
-
Weber ANR, McManus RM, Hornung V, Geyer M, Kuemmerle-Deschner JB, Latz E. The expanding role of the NLRP3 inflammasome from periodic fevers to therapeutic targets. Nat Immunol. 2025 Sep; 26(9):1453-1466.
-
Gorasiya S, Mushi J, Yoganathan S, Barasa L, Pekson R, Ashby CR, Reznik SE. N,N-Diethylacetamide and N,N-Dipropylacetamide inhibit the NF-kB pathway in in vitro, ex vivo and in vivo models of inflammation-induced preterm birth. Sci Rep. 2025 Aug 14; 15(1):29861.